Technical Analysis for REPH - Recro Pharma, Inc.

Grade Last Price % Change Price Change
grade C 9.0 -2.60% -0.24
REPH closed down 2.6 percent on Monday, March 18, 2019, on 2.0 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical REPH trend table...

Date Alert Name Type % Chg
Mar 15 20 DMA Support Bullish -2.60%
Mar 15 Pocket Pivot Bullish Swing Setup -2.60%
Mar 14 20 DMA Support Bullish -0.11%
Mar 13 MACD Bearish Signal Line Cross Bearish -0.66%
Mar 8 20 DMA Support Bullish -4.15%
Mar 8 1,2,3 Pullback Bullish Bullish Swing Setup -4.15%
Mar 8 180 Bullish Setup Bullish Swing Setup -4.15%
Mar 8 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -4.15%
Mar 8 Outside Day Range Expansion -4.15%
Mar 7 1,2,3 Pullback Bullish Bullish Swing Setup -0.11%

Older signals for REPH ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Recro Pharma, Inc., a clinical stage specialty pharmaceutical company, is engaged in the development of various non-opioid therapeutics for the treatment of pain and related conditions in the United States. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. It has a license agreement with Orion Corporation for the development and commercialization of Dex and Fado. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.
Medicine Pain Chronic Pain Perception Stage Specialty Pharmaceutical Imidazoles Neuropathic Pain Sensory Systems
Is REPH a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 13.05
52 Week Low 4.78
Average Volume 166,000
200-Day Moving Average 6.9461
50-Day Moving Average 8.427
20-Day Moving Average 8.94
10-Day Moving Average 9.166
Average True Range 0.4851
ADX 31.44
+DI 22.8614
-DI 12.8326
Chandelier Exit (Long, 3 ATRs ) 8.8647
Chandelier Exit (Short, 3 ATRs ) 9.575299999999999
Upper Bollinger Band 9.7114
Lower Bollinger Band 8.1686
Percent B (%b) 0.54
BandWidth 17.257271
MACD Line 0.222
MACD Signal Line 0.2618
MACD Histogram -0.0398
Fundamentals Value
Market Cap 171.53 Million
Num Shares 19.1 Million
EPS -2.12
Price-to-Earnings (P/E) Ratio -4.25
Price-to-Sales 2.35
Price-to-Book 2.89
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.78
Resistance 3 (R3) 9.86 9.67 9.65
Resistance 2 (R2) 9.67 9.47 9.63 9.61
Resistance 1 (R1) 9.34 9.35 9.24 9.26 9.56
Pivot Point 9.15 9.15 9.11 9.11 9.15
Support 1 (S1) 8.82 8.95 8.73 8.74 8.44
Support 2 (S2) 8.63 8.83 8.60 8.39
Support 3 (S3) 8.30 8.63 8.35
Support 4 (S4) 8.22